Press release
Insmed To Present at the SVB Securities Global Biopharma Conference
BRIDGEWATER, N.J., Feb. 7, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of
About this update from Insmed Incorporated
[{"type":"text","content":"BRIDGEWATER, N.J., Feb. 7, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 12:00 p.m. ET.\nThe fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. The webcast will be archived for a period of 30 days following the conclusion of the live event.\nAbout InsmedInsmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan. For more information, visit www.insmed.com.\nContact:Investors:\nEleanor BarisserAssociate Director, Investor Relations Insmed(718) [email protected] \nMedia:\nMandy Fahey Executive Director, Corporate CommunicationsInsmed(732) [email protected]\n\n\n\n\n View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-present-at-the-svb-securities-global-biopharma-conference-301740029.html\nSOURCE Insmed Incorporated","length":3960,"tagName":"div"}]